SCHEMBL3732148

SCHEMBL3732148

CNC(=O)[C@@H](N[C@H](CCc1cnc(Cl)cn1)c1ccc(F)c(C)c1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.39
ALDH1A1 P00352 5/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
S1PR1 P21453 2/20 0.35
GPR88 Q9GZN0 1/20 0.35
EP300 Q09472 2/20 0.34
CTSA P10619 1/20 0.33
AKT1 P31749 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GPR39 O43194 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
MMP14 P50281 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3732152 1.00 S1PR3 (0.39) S1PR3ALDH1A1SMN1; SMN2S1PR1GPR88
SCHEMBL3736099 1.00 S1PR3 (0.39) S1PR3ALDH1A1SMN1; SMN2S1PR1GPR88
SCHEMBL3736172 1.00 S1PR3 (0.39) S1PR3ALDH1A1SMN1; SMN2S1PR1GPR88
SCHEMBL3736092 1.00 S1PR3 (0.39) S1PR3ALDH1A1SMN1; SMN2S1PR1GPR88
SCHEMBL3739491 1.00 S1PR3 (0.39) S1PR3ALDH1A1SMN1; SMN2S1PR1GPR88
SCHEMBL3734506 1.00 S1PR3 (0.39) S1PR3ALDH1A1SMN1; SMN2S1PR1GPR88
SCHEMBL3727880 0.91 GPR88 (0.36) S1PR3ALDH1A1SMN1; SMN2GPR88AKT1
SCHEMBL3736006 0.91 GPR88 (0.36) S1PR3ALDH1A1SMN1; SMN2GPR88AKT1
SCHEMBL3727877 0.91 GPR88 (0.36) S1PR3ALDH1A1SMN1; SMN2GPR88AKT1
SCHEMBL8171667 0.89 S1PR3 (0.34) S1PR3S1PR1CTSAAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114867-B1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-7829563-B2 Aminoamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2010-11-09 US disclosed
US-7829563-B2 Aminoamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2010-11-09 US disclosed
US-7829563-B2 Aminoamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2010-11-09 US disclosed
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-09-11 US disclosed
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-09-11 US disclosed
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HCRTR1, HCRTR2, HRH3 S1PR3 339/4885ALDH1A1 1610/4885SMN1; SMN2 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.